Prognostic factors of metastatic testicular non-seminomatous germ cell tumors after chemotherapy

Liao, Tzu-Yao; Liaw, Chuang-Chi; Chuang, Cheng-Keng; Chang, Ying-Hsu; Hsu, Cheng‐Lung; Peng, Meng-Ting; Chang, John Wen‐Cheng

doi:10.1016/j.jcrpr.2018.03.003

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current treatment options for TGCT include orchiectomy, radiation therapy and chemotherapy ( Oing et al, 2018 ). Although the survivability rate is high (90%–95%), chemoresistance occurs in 10%–15% of tumors leading to a dramatic prognosis and poor quality of life ( Liao et al, 2018 ; Groot et al, 2020 ; Hellesnes et al, 2021 ). Furthermore, the chemotherapy agents used, bleomycin, cisplatin and etoposide have been associated with epigenetic processes, which call for further studies concerning the consequences of treatment, as well as the possible identification of new therapeutic agents.…”

Section: Testicular Cancer (Tca)mentioning

confidence: 99%

H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets

Burlibaşa

Nicu

Chifiriuc

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

During the last decades, male urogenital cancers (including prostate, renal, bladder and testicular cancers) have become one of the most frequently encountered malignancies affecting all ages. While their great variety has promoted the development of various diagnosis, treatment and monitoring strategies, some aspects such as the common involvement of epigenetic mechanisms are still not elucidated. Epigenetic processes have come into the spotlight in the past years as important players in the initiation and progression of tumors, leading to a plethora of studies highlighting their potential as biomarkers for diagnosis, staging, prognosis, and even as therapeutic targets. Thus, fostering research on the various epigenetic mechanisms and their roles in cancer remains a priority for the scientific community. This review focuses on one of the main epigenetic mechanisms, namely, the methylation of the histone H3 at various sites and its involvement in male urogenital cancers. This histone modification presents a great interest due to its modulatory effect on gene expression, leading either to activation (e.g., H3K4me3, H3K36me3) or repression (e.g., H3K27me3, H3K9me3). In the last few years, growing evidence has demonstrated the aberrant expression of enzymes that methylate/demethylate histone H3 in cancer and inflammatory diseases, that might contribute to the initiation and progression of such disorders. We highlight how these particular epigenetic modifications are emerging as potential diagnostic and prognostic biomarkers or targets for the treatment of urogenital cancers.

show abstract

Section: Testicular Cancer (Tca)mentioning

confidence: 99%

H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets

Burlibaşa

Nicu

Chifiriuc

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…TGCTs have an impressive 5-year survivability rate of approximately 95%, that, even in case of metastases, could reach 90% (Liao et al, 2018). Current treatment options include surgery, radiation therapy, and chemotherapy (Oing et al, 2018).…”

Section: Tgct Therapymentioning

confidence: 99%

Epigenetics and Testicular Cancer: Bridging the Gap Between Fundamental Biology and Patient Care

Nicu

Medar

Chifiriuc

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Testicular cancer is the most common solid tumor affecting young males. Most testicular cancers are testicular germ cell tumors (TGCTs), which are divided into seminomas (SGCTs) and non-seminomatous testicular germ cell tumors (NSGCTs). During their development, primordial germ cells (PGCs) undergo epigenetic modifications and any disturbances in their pattern might lead to cancer development. The present study provides a comprehensive review of the epigenetic mechanisms–DNA methylation, histone post-translational modifications, bivalent marks, non-coding RNA–associated with TGCT susceptibility, initiation, progression and response to chemotherapy. Another important purpose of this review is to highlight the recent investigations regarding the identification and development of epigenetic biomarkers as powerful tools for the diagnostic, prognostic and especially for epigenetic-based therapy.

show abstract

Prognostic factors of metastatic testicular non-seminomatous germ cell tumors after chemotherapy

Cited by 2 publications

References 27 publications

H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets

H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets

Epigenetics and Testicular Cancer: Bridging the Gap Between Fundamental Biology and Patient Care

Contact Info

Product

Resources

About